ProShare Advisors LLC Boosts Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

ProShare Advisors LLC lifted its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 24.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,357 shares of the company’s stock after acquiring an additional 8,126 shares during the quarter. ProShare Advisors LLC’s holdings in Vir Biotechnology were worth $1,955,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. AGF Investments LLC increased its holdings in Vir Biotechnology by 35.8% during the second quarter. AGF Investments LLC now owns 13,551 shares of the company’s stock valued at $641,000 after buying an additional 3,569 shares during the period. CNA Financial Corp increased its holdings in Vir Biotechnology by 9.8% during the second quarter. CNA Financial Corp now owns 11,942 shares of the company’s stock valued at $565,000 after buying an additional 1,070 shares during the period. State of Wisconsin Investment Board increased its holdings in Vir Biotechnology by 0.9% during the second quarter. State of Wisconsin Investment Board now owns 79,300 shares of the company’s stock valued at $3,749,000 after buying an additional 700 shares during the period. Legal & General Group Plc increased its holdings in Vir Biotechnology by 57.8% during the second quarter. Legal & General Group Plc now owns 44,680 shares of the company’s stock valued at $2,113,000 after buying an additional 16,371 shares during the period. Finally, Bank of Nova Scotia increased its holdings in Vir Biotechnology by 47.6% during the second quarter. Bank of Nova Scotia now owns 10,670 shares of the company’s stock valued at $504,000 after buying an additional 3,442 shares during the period. 58.62% of the stock is currently owned by institutional investors and hedge funds.

In other Vir Biotechnology news, Director Vicki L. Sato sold 15,174 shares of Vir Biotechnology stock in a transaction on Friday, September 17th. The shares were sold at an average price of $52.48, for a total value of $796,331.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Phillip Pang sold 5,000 shares of Vir Biotechnology stock in a transaction on Wednesday, October 6th. The shares were sold at an average price of $34.56, for a total transaction of $172,800.00. The disclosure for this sale can be found here. Insiders have sold 127,132 shares of company stock valued at $5,665,140 over the last 90 days. 37.20% of the stock is currently owned by insiders.

NASDAQ VIR opened at $40.52 on Thursday. The company has a market capitalization of $5.29 billion, a PE ratio of -17.17 and a beta of -1.68. The company has a fifty day moving average of $44.93 and a 200 day moving average of $44.02. Vir Biotechnology, Inc. has a 1 year low of $25.31 and a 1 year high of $141.01.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, August 5th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $1.14. The company had revenue of $177.07 million during the quarter, compared to the consensus estimate of $57.88 million. Vir Biotechnology had a negative net margin of 162.75% and a negative return on equity of 40.77%. As a group, equities analysts predict that Vir Biotechnology, Inc. will post -1.17 earnings per share for the current year.

Several equities research analysts have weighed in on VIR shares. Needham & Company LLC restated a “buy” rating and issued a $80.00 target price on shares of Vir Biotechnology in a research note on Monday, June 28th. Zacks Investment Research downgraded shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Wednesday. TheStreet upgraded shares of Vir Biotechnology from a “d” rating to a “c-” rating in a research note on Friday, August 20th. Barclays lowered their target price on shares of Vir Biotechnology from $96.00 to $71.00 and set an “overweight” rating for the company in a research note on Friday, August 6th. Finally, The Goldman Sachs Group downgraded shares of Vir Biotechnology from a “buy” rating to a “neutral” rating and lowered their target price for the company from $64.00 to $62.00 in a research note on Wednesday, September 22nd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $63.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis.

Recommended Story: What is a put option?

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.